Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospit...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 21; no. 1; pp. 1 - 807
Main Authors Li, Shuai, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 13.07.2021
BioMed Central
BMC
Subjects
Breast cancer
Cancer therapies
Chemotherapy
Drug therapy
Endocrine therapy
ErbB-2 protein
Escalation
HER2
Hormone receptor
Medical prognosis
Menopause
Menstruation
Metastasis
Monoclonal antibodies
Multivariate analysis
Patient outcomes
Patients
Prognosis
Radiation therapy
Regression analysis
Surgery
Survival
Targeted cancer therapy
Trastuzumab
Tumors
Womens health
China
Online AccessGet full text

Cover

Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Keywords: Breast cancer, Hormone receptor, HER2, Trastuzumab, Endocrine therapy, Escalation
AbstractList Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab.
Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P <  0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37–0.73, P <  0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22–0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab.
Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P  <  0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group ( P  = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37–0.73, P  <  0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively ( P  = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22–0.67, P  = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab.
BACKGROUNDTrastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. METHODSER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. RESULTSA total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P <  0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P <  0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). CONCLUSIONER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab.
Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P <  0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37–0.73, P <  0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22–0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab.
Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruijin Hospital between Jan. 2009 and Dec. 2017 were retrospectively included. Eligible patients were grouped as HER2-negative (HER2-neg) or HER2-positive with trastuzumab treatment (HER2-pos-T). Kaplan-Meier analysis and Cox proportional hazards model were used to compare the disease-free survival (DFS) and overall survival (OS) between these two groups. Results A total of 3761 patients were enrolled: 3313 in the HER2-neg group and 448 in the HER2-pos-T group. Patients in the HER2-pos-T group were associated with pre/peri-menopause, higher histological grade, LVI, higher Ki-67 level, lower ER and PR levels (all P < 0.05). At a median follow-up of 62 months, 443 DFS events and 191 deaths were observed. The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). Conclusion ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients, indicating HER2-positivity itself may not be an adverse factor for ER+ patients in the era of trastuzumab. Keywords: Breast cancer, Hormone receptor, HER2, Trastuzumab, Endocrine therapy, Escalation
ArticleNumber 807
Audience Academic
Author Chen, Weiguo
Shen, Kunwei
Zhu, Li
Chen, Xiaosong
Li, Shuai
Li, Yafen
Wu, Jiayi
Huang, Ou
He, Jianrong
Author_xml – sequence: 1
  givenname: Shuai
  surname: Li
  fullname: Li, Shuai
– sequence: 2
  givenname: Jiayi
  surname: Wu
  fullname: Wu, Jiayi
– sequence: 3
  givenname: Ou
  surname: Huang
  fullname: Huang, Ou
– sequence: 4
  givenname: Jianrong
  surname: He
  fullname: He, Jianrong
– sequence: 5
  givenname: Li
  surname: Zhu
  fullname: Zhu, Li
– sequence: 6
  givenname: Weiguo
  surname: Chen
  fullname: Chen, Weiguo
– sequence: 7
  givenname: Yafen
  surname: Li
  fullname: Li, Yafen
– sequence: 8
  givenname: Xiaosong
  surname: Chen
  fullname: Chen, Xiaosong
– sequence: 9
  givenname: Kunwei
  surname: Shen
  fullname: Shen, Kunwei
BookMark eNptkt9qFDEUxgdR7B99Aa8CgihlapJJJjNeCKVUWygIVa_DmeTMbspssiYZq76GL2y2W2pXJBeTnPy-L3MO30H12AePVfWC0WPGuvZtYrzrZE05q2knpazFo2qfCcVqLqh6_GC_Vx2kdE0pUx3tnlZ7jeCyVYzuV79PJ-edgYmYJUQwGaNL2ZlEwFtiXUJISMKcTVhhIs6Ts6sjMsRSzsSANxjfESDldg1FGTwZMN8genJ-dsWPyBqyQ58TyUWS0ZIbl5flUOTzr3kFw-07G7a-Z59VT0aYEj6_-x5WXz-cfTk9ry8_fbw4PbmsjeRU1INtLFDbKtPCYE1pTTEsIwHec2h6yYG1qm8tp3IUPZeWcWa5olyIBu0wNIfVxdbXBrjW6-hWEH_qAE7fFkJcaIhlFhPqDmHko-17aY0AOw6tpNKAxJYygY0oXu-3Xut5WKE1pY8I047p7o13S70I33XHVadoXwxe3xnE8G3GlPXKJYPTBB7DnDSXkknVtmKDvvwHvQ5z9GVUG6rhQnas_UstoDTg_BjKu2Zjqk9axZtGcbb57-P_UGVZXDlT8ja6Ut8RvNkRFCbjj7yAOSV98flql331gF0iTHmZwjRnF3zaBfkWNDGkFHG8HxyjepN1vc26LlnXt1nXovkDUbfvnQ
CitedBy_id crossref_primary_10_1186_s12885_022_10136_y
Cites_doi 10.1007/s12094-019-02163-2
10.1200/JCO.2006.09.2775
10.1126/science.2470152
10.1016/S1470-2045(13)70384-X
10.1200/JCO.2009.25.6529
10.1371/journal.pmed.1000279
10.1016/S1470-2045(14)70080-4
10.1001/jama.2018.19323
10.1200/JCO.19.00126
10.1016/j.ejca.2019.05.004
10.1056/NEJMoa1404037
10.1056/NEJMoa1803164
10.1186/1471-2407-13-390
10.1056/NEJMoa053028
10.1200/JCO.2018.77.8738
10.1200/JCO.2014.55.5730
10.1056/NEJMoa1412379
10.1016/j.ejca.2017.10.033
10.1007/s10549-007-9660-2
10.1093/annonc/mdt287
10.1200/JCO.2013.50.9984
10.1016/S0140-6736(16)32616-2
10.1200/JCO.2015.65.9573
10.1200/JCO.19.00066
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12885-021-08555-4
DatabaseName CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 807
ExternalDocumentID oai_doaj_org_article_8eaf2fd995dc4adfb6505ca5e6014e34
A672337214
10_1186_s12885_021_08555_4
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
-A0
0R~
23N
2WC
3V.
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AFGXO
ABVAZ
AFNRJ
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c5204-bd3da0d67c6abdc78071e128a292a3952a16796d205f4925d121d2702443edbb3
IEDL.DBID RPM
ISSN 1471-2407
IngestDate Tue Oct 22 15:13:42 EDT 2024
Tue Sep 17 21:29:23 EDT 2024
Sat Oct 05 05:22:47 EDT 2024
Thu Oct 10 16:19:35 EDT 2024
Thu Feb 22 23:50:24 EST 2024
Fri Feb 02 04:19:14 EST 2024
Thu Aug 01 19:29:20 EDT 2024
Tue Aug 20 22:12:54 EDT 2024
Thu Sep 12 17:02:30 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5204-bd3da0d67c6abdc78071e128a292a3952a16796d205f4925d121d2702443edbb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278709/
PMID 34256710
PQID 2553245816
PQPubID 44074
ParticipantIDs doaj_primary_oai_doaj_org_article_8eaf2fd995dc4adfb6505ca5e6014e34
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8278709
proquest_miscellaneous_2551576649
proquest_journals_2553245816
gale_infotracmisc_A672337214
gale_infotracacademiconefile_A672337214
gale_incontextgauss_ISR_A672337214
gale_healthsolutions_A672337214
crossref_primary_10_1186_s12885_021_08555_4
PublicationCentury 2000
PublicationDate 20210713
PublicationDateYYYYMMDD 2021-07-13
PublicationDate_xml – month: 7
  year: 2021
  text: 20210713
  day: 13
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC cancer
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AG Waks (8555_CR2) 2019; 321
F Bray (8555_CR1) 2018; 68
DJ Slamon (8555_CR5) 1989; 244
HA Kim (8555_CR27) 2020; 38
HJ Burstein (8555_CR22) 2016; 34
Y Tong (8555_CR13) 2018; 89
PA Francis (8555_CR25) 2018; 379
F Perrone (8555_CR26) 2019; 118
SM Tolaney (8555_CR11) 2019; 37
O Pagani (8555_CR24) 2014; 371
SE Jones (8555_CR10) 2013; 14
AC Wolff (8555_CR16) 2013; 31
H Joensuu (8555_CR20) 2006; 354
DJ Slamon (8555_CR4) 1987; 10
L Gianni (8555_CR21) 2014; 15
D Cameron (8555_CR7) 2017; 389
AC Wolff (8555_CR17) 2018; 36
F Montemurro (8555_CR3) 2013; 24
K Chen (8555_CR18) 2019; 22
ME Hammond (8555_CR14) 2010; 28
AC Wolff (8555_CR15) 2007; 25
FM Blows (8555_CR19) 2010; 7
EA Perez (8555_CR8) 2014; 32
R Lisa (8555_CR6) 2008; 109
D Slamon (8555_CR9) 2012; 366
PA Francis (8555_CR23) 2015; 372
X Chen (8555_CR12) 2013; 13
References_xml – volume: 22
  start-page: 576
  issue: 4
  year: 2019
  ident: 8555_CR18
  publication-title: Clin Transl Oncol doi
  doi: 10.1007/s12094-019-02163-2
  contributor:
    fullname: K Chen
– volume: 25
  start-page: 118
  year: 2007
  ident: 8555_CR15
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.2775
  contributor:
    fullname: AC Wolff
– volume: 244
  start-page: 707
  issue: 4905
  year: 1989
  ident: 8555_CR5
  publication-title: Science
  doi: 10.1126/science.2470152
  contributor:
    fullname: DJ Slamon
– volume: 14
  start-page: 1121
  issue: 11
  year: 2013
  ident: 8555_CR10
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70384-X
  contributor:
    fullname: SE Jones
– volume: 28
  start-page: 2784
  issue: 16
  year: 2010
  ident: 8555_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.6529
  contributor:
    fullname: ME Hammond
– volume: 10
  start-page: 334
  issue: 4785
  year: 1987
  ident: 8555_CR4
  publication-title: Science
  contributor:
    fullname: DJ Slamon
– volume: 7
  issue: 5
  year: 2010
  ident: 8555_CR19
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000279
  contributor:
    fullname: FM Blows
– volume: 15
  start-page: 640
  issue: 6
  year: 2014
  ident: 8555_CR21
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70080-4
  contributor:
    fullname: L Gianni
– volume: 321
  start-page: 288
  issue: 3
  year: 2019
  ident: 8555_CR2
  publication-title: JAMA
  doi: 10.1001/jama.2018.19323
  contributor:
    fullname: AG Waks
– volume: 38
  start-page: 434
  issue: 5
  year: 2020
  ident: 8555_CR27
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.19.00126
  contributor:
    fullname: HA Kim
– volume: 118
  start-page: 178
  year: 2019
  ident: 8555_CR26
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2019.05.004
  contributor:
    fullname: F Perrone
– volume: 371
  start-page: 107
  issue: 2
  year: 2014
  ident: 8555_CR24
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1404037
  contributor:
    fullname: O Pagani
– volume: 379
  start-page: 122
  issue: 2
  year: 2018
  ident: 8555_CR25
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1803164
  contributor:
    fullname: PA Francis
– volume: 13
  start-page: 390
  issue: 1
  year: 2013
  ident: 8555_CR12
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-13-390
  contributor:
    fullname: X Chen
– volume: 354
  start-page: 809
  issue: 8
  year: 2006
  ident: 8555_CR20
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa053028
  contributor:
    fullname: H Joensuu
– volume: 36
  start-page: 2105
  issue: 20
  year: 2018
  ident: 8555_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.77.8738
  contributor:
    fullname: AC Wolff
– volume: 32
  start-page: 3744
  issue: 33
  year: 2014
  ident: 8555_CR8
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.55.5730
  contributor:
    fullname: EA Perez
– volume: 372
  start-page: 436
  issue: 5
  year: 2015
  ident: 8555_CR23
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1412379
  contributor:
    fullname: PA Francis
– volume: 89
  start-page: 9
  year: 2018
  ident: 8555_CR13
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2017.10.033
  contributor:
    fullname: Y Tong
– volume: 109
  start-page: 351
  issue: 2
  year: 2008
  ident: 8555_CR6
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-007-9660-2
  contributor:
    fullname: R Lisa
– volume: 24
  start-page: 2715
  issue: 11
  year: 2013
  ident: 8555_CR3
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt287
  contributor:
    fullname: F Montemurro
– volume: 31
  start-page: 3997e4013
  issue: 31
  year: 2013
  ident: 8555_CR16
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.50.9984
  contributor:
    fullname: AC Wolff
– volume: 389
  start-page: 1195
  issue: 10075
  year: 2017
  ident: 8555_CR7
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32616-2
  contributor:
    fullname: D Cameron
– volume: 366
  start-page: 1273
  issue: 7
  year: 2012
  ident: 8555_CR9
  publication-title: N Engl J Med
  contributor:
    fullname: D Slamon
– volume: 68
  start-page: 394
  issue: 6
  year: 2018
  ident: 8555_CR1
  publication-title: CA: A Cancer J Clin
  contributor:
    fullname: F Bray
– volume: 34
  start-page: 1689
  issue: 14
  year: 2016
  ident: 8555_CR22
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.65.9573
  contributor:
    fullname: HJ Burstein
– volume: 37
  start-page: 1868
  issue: 22
  year: 2019
  ident: 8555_CR11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.00066
  contributor:
    fullname: SM Tolaney
SSID ssj0017808
Score 2.386633
Snippet Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with...
Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab,...
Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to...
BACKGROUNDTrastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab,...
Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 1
SubjectTerms Breast cancer
Cancer therapies
Chemotherapy
Drug therapy
Endocrine therapy
ErbB-2 protein
Escalation
HER2
Hormone receptor
Medical prognosis
Menopause
Menstruation
Metastasis
Monoclonal antibodies
Multivariate analysis
Patient outcomes
Patients
Prognosis
Radiation therapy
Regression analysis
Surgery
Survival
Targeted cancer therapy
Trastuzumab
Tumors
Womens health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikCBQxC4rCKmvgVh1tBWy1IcFio1JvlV6BSyaJmc-nf6B9mxvGuGjhw4bjrL9rNzNiZL575TMgbnkTYpCpF64GgyE6VTmteqhA1a4OvK5cKZL-o1an4dCbPbhz1hTVhkzzwZLgjHW3HutC2MnhhQ-cgpZDeyghMQkQ-KYHWckem8v5Boyu9a5HR6miAVVhjJzK-DpRSlmL2GEpq_X-vyX_WSd548JzcI3dzxkiPp396n9yK_QNy-3PeE39IrrO05wX1c_FlavtA8wYM3YxbiK040POeLtcL6rAYfUs9Ov3yHbXU7w8kpLl2i66Wa7agWXl1oKkmPQaKr27hA1w-Xo0_rUu_g9hyj31ETk-W3z6synzUQuklq0TpAg-2CqrxyrrgwXxNHcFolrXM8lYyi9s1KoBbO5QzDDWrA7ayCcFjcI4_Jgf9po9PCGVVB2lMBMbeMBGCsx1QLq9t1XGvPa8LsthZ3vyaFDVMYiJamclPBvxkkp-MKMh7dM4eiWrY6QuIEZNjxPwrRgryEl1rptbS_Zw2x6phnAMHBsTrhEBFjB5Lbr7bcRjMx6_rGehtBnUbsLK3uYMB7htFtGbIwxkSpqyfD-9izOQlYzDA7SC5lbpWBXm1H8YrsQyuj5sxYWogiEq0BWlmsTkz0HykP_-RZMM1w8W5ffo_LPqM3GFpNjVlzQ_JwfZyjM8hO9u6F2ki_gbJyThj
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96B-KL-Imrp0YRfFjKtflq6ovcyR6r4CGrB_cW0iQ9D7Q9t9sX_w3_YWey2WoVfGwzbelMZjKTmfmFkJc8grBJlYnKQYAiG5XVWvNM-aBZ5V2R17FA9lQtz8T7c3meNtz6VFa5s4nRUPvO4R75Ibi-sPZLXag3V98zPDUKs6vpCI3rZJ8VAtO0-8eL04-rMY9Q6lzvWmW0OuzBGmvsSMZtQSllJibLUUTt_9c2_10v-ccCdHKb3EqeIz3aivoOuRbau-TGh5Qbv0d-JojPr9RNQZipbT1NiRjaDRv439DTy5YuVnNaY1H6hjoU_vo1tdSNBxPSVMNFl4sVm9OEwNrTWJsePMUtXLiAx4cfwzdbx-8gbTbS3idnJ4vPb5dZOnIhc5LlIqs99zb3qnTK1t4B-8oiANMsq5jllWQW0zbKg3gbhDX0BSs8trQJwYOva_6A7LVdGx4SyvIG3JkAkXvJhPe1bSD0ctrmDXfa8WJG5jvOm6stsoaJEYlWZisnA3IyUU5GzMgxCmekRFTseKNbX5ikZEYH27DGV5X0Tljf1OB-SmdlgKhTBA4veYaiNdsW01G3zZEqGecQCwPFi0iByBgtlt5c2KHvzbtPqwnRq0TUdMBlZ1MnA_w3gmlNKA8mlKC6bjq8m2MmmY7e_J7oM_J8HMYnsRyuDd0QaQoIFJWoZqSczM0Jg6Yj7eWXCB-uGRrp6tH_P_6Y3GRRT8qs4Adkb7MewhPwvzb106RkvwDL5DAH
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LixNBEG7WFcSL-MToqq0IHsJopl_TI4issksU1kM0sLemX7O7sE40kwH1b_iHrep0oqMLHpP-ZkLq0dM1VfUVIU95ImGTqhC1hwBFNqpwWvNChahZHXw5calA9oOazsX7Y3m8QzbjjrIAuwtDO5wnNV-eP__29ftrcPhXyeG1etHBHquxzxhf9kkpC3GJXGaCC7T4I_E7q1DpNKGuhA0ZswrVponmwnsMHlSJz__fXfvvSso_Hk2H18m1fKak-2sjuEF2YnuTXDnKWfNb5Gcm_zynfkjPTG0baE7R0EW_AuuLHT1r6cFsTB2Wq6-oR7NYvqSW-u3IQpqru-j0YMbGNHOzdjRVrcdA8eUufIDL-x_9Z-vS7yC22GJvk_nhwae30yIPYyi8ZBNRuMCDnQRVeWVd8CDKqowgNMtqZnktmcWEjgqg-AYJD0PJyoDNbkLwGJzjd8huu2jjXULZpIGDToSYvmIiBGcbCMq8tpOGe-15OSLjjeTNlzXnhkmxilZmrScDejJJT0aMyBtUzhaJfNnpi8XyxGT3MzrahjWhrmXwwobGwcFUeisjxKMicrjJI1StWTefbr3e7KuKcQ5RMiCeJARyZrRYlHNi-64z7z7OBqBnGdQsQMre5h4H-N9IszVA7g2Q4NR-uLyxMbPxCQPRHxx_pS7ViDzeLuOVWCjXxkWfMCWEkErUI1INbHMgoOFKe3aaiMU1w-27vvdfYdwnV1lylaoo-R7ZXS37-AAOZyv3MHncL2BKNNI
  priority: 102
  providerName: Scholars Portal
Title Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
URI https://www.proquest.com/docview/2553245816
https://search.proquest.com/docview/2551576649
https://pubmed.ncbi.nlm.nih.gov/PMC8278709
https://doaj.org/article/8eaf2fd995dc4adfb6505ca5e6014e34
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe2ISFeEJ-iMIpBSDxUWRM7dhze1qlTQeo0FSZNvFj-yqi0plPTvPBv8A9zdp1qgTdeIqU-t43vzrmzf_czQh9pIGFjPMlLAwkKq3iihaAJt06Q0pos1QEge8FnV_nXa3Z9gFhXCxNA-0YvT-rb1Um9_BmwlXcrM-5wYuPL-Zkg3szK8SE6LCjtUvS4dVCIVHTVMYKPG5iAhS9C9iuBjLHEn8RDwVJ54atm772MAmf_vzPz32jJe6-f8yfocYwb8enu_z1FB65-hh7O4874c_Q7EnzeYtOnYMaqtjhuw-B1uwULcw1e1ni6GGHtIelbbLzqN5-xwmZ_LCGOCC48my7ICEf-1QYHZLqz2C_gwg10b3-1K6XD73jZZC_7Al2dT7-fzZJ44EJiGEnzRFtqVWp5YbjS1sBIFpmD8VOkJIqWjCi_acMtKLfypIY2I5n1BW15Tp3Vmr5ER_W6dq8QJmkFwYyDvL0gubVaVZB4GaHSihphaDZAo27k5d2OV0OGfERwuVOZBJXJoDKZD9DEK2cv6TmxwwfrzY2MliGFUxWpbFkya3JlKw3BJzOKOcg5c0fhS9551cpdgenes-UpLwilkAmDxIcg4Xkxag-8uVFt08gv3xY9oU9RqFrDKBsV6xjguT2VVk_yuCcJjmv6zZ2NyThxNBIyPAhxmcj4AL3fN_ueHgxXu3UbZDJIE3leDlDRs83eAPVbwJcCeXj0ndf_3fMNekSCNxVJRo_R0XbTurcQmG31ENzxuhiiB5PpxeViGJY34DrPBVwXkx_D4Kh_ALjhPQs
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8VQXCjUIicMqauJXHC6ooK220PawtNLeLL9SKkFSNpsLf4M_zNjrDQQkjom_JMqMZ-yxZz4j9JpGEjYuMlZZCFB4LTIjJc2E85JUzha5iQmyZ2J-wT4u-TItuHUprXLrE6Ojdq0Na-QHMPWFsZ_LQry7_p6FU6PC7mo6QuMmusUoZaGfl8sh4CpKmcttoYwUBx34YhnqkcOiIOc8Y6PBKHL2_-uZ_86W_GP4ObqP7qV5Iz7cKPoBuuGbh-j2adoZf4R-JoLPr9iOKZixbhxO2zC47dfwt77DVw2eLabYhJT0NbZB9au3WGM7HEuIUwYXns8WZIoT_2qHY2a6dzgs4MIFPN7_6L9pE78TsNmAfYwujmbnH-ZZOnAhs5zkLDOOOp07UVqhjbMgvrLwIDRNKqJpxYkOmzbCgXLrQGroClK4UNDGGPXOGPoE7TRt43cRJnkNkxkPcXtJmHNG1xB4WanzmlppaTFB063k1fWGV0PFeEQKtdGTAj2pqCfFJuh9UM6ADJzY8Ua7ulTJxJT0uia1qyruLNOuNjD55FZzDzEn8xResh9UqzYFpoNlq0NREkohEgbEq4gIvBhNSLy51H3XqePPixHoTQLVLUjZ6lTHAP8dqLRGyL0REgzXjpu3fUwlx9Gp3918gl4OzeHJkAzX-LaPmALCRMGqCSpHfXMkoHFLc_UlkodLElx09fT_H99Hd-bnpyfq5Pjs0zN0l0SbKbOC7qGd9ar3z2EmtjYvorn9AiBmMY4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgSBMvfKMVBjMIiYcqbWInjsPbGJ06YNNUmDTxYvkro2JNq6Z52d_gD3PtOlUz3vbY-DhN4mPHNz73GKEP1JuwZSxKCw0BSlaySHFOI2YsJ4XRSay8QPaMjS_Sr5fZ5dZWX160r9V0UF3PBtX0t9dWLmZ62OrEhuenR5w4mhXDhSmH99ED6LMkbwP1sICQ85i3OTKcDWsYhrlLRXbfA7Msi9x-PBT4ynKXO7v1SvLO_f-Pz7c1k1svoePH6Fd7-WvtyZ9Bs1IDfXPL2fFO9_cEPQpTU3y4hjxF92z1DO2ehsX35-hv8BC9xrrr8oxlZXBY6cHzZgUktjWeVng06WPlVO8rrB27lp-wxHqz8yEOIjE8Hk1IHweL1xp78bs12H0jhh9QvblpZlL5_3HYaIN9gS6ORz-PxlHY0yHSGYnTSBlqZGxYrplURkMz5YmFxpGkIJIWGZFuXYgZ4E_pfBNNQhLjcubSlFqjFH2Jdqp5ZfcQJnEJ8yVrFclJaoySJcR2msu4pJprmvRQv21WsVhbdwgf8nAm1nwQwAfh-SDSHvrsWn6DdLbb_sB8eSVC4whuZUlKUxSZ0ak0pYL5baZlZiGsTS2Fkxw43oh1Dutm8BCHLCeUQrANiPce4aw3KqftuZJNXYuTH5MO6GMAlXN4ylqGVAm4b-fW1UHud5AwNuhucUtgEcamWkAQCbPojCesh95til1Np7er7LzxmAQiUZYWPZR3iN95QN0SoLP3Jw_0fXXnmgdo9_zLsfh-cvbtNXpIfK_No4Tuo53VsrFvYBq4Um99h_8HaZJcKw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+characteristics+and+disease+outcomes+in+ER%2B+breast+cancer%3A+a+comparison+between+HER2%2B+patients+treated+with+trastuzumab+and+HER2-+patients&rft.jtitle=BMC+cancer&rft.au=Li%2C+Yafen&rft.au=He%2C+Jianrong&rft.au=Chen%2C+Weiguo&rft.au=Shen%2C+Kunwei&rft.date=2021-07-13&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-021-08555-4&rft.externalDBID=n%2Fa&rft.externalDocID=A672337214
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon